FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999808560> ?p ?o ?g. }

• W1999808560 endingPage "A119" @default.
• W1999808560 startingPage "A119" @default.
• W1999808560 abstract "COST-EFFECTIVENESS OF ARIPIPRAZOLE FOR THE MANAGEMENT OF SCHIZOPHRENIA INTHE UNITED KINGDOM Davies A,Vardeva K, Loze JY, L’Italien GJ, Sennfalt K, Pugner K, van Baardewijk M Oxford Outcomes (UK), Oxford, England, Bristol-Myers Squibb, Uxbridge, UK, Otsuka Pharmaceutical France, Paris, France, Bristol-Myers Squibb,Wallingford, CT, USA, Bristol-Myers Squibb, Bromma, Sweden, Bristol-Myers Squibb, Braine l’Alleud, Belgium OBJECTIVE: To evaluate the cost-effectiveness of atypical antipsychotic treatment sequences for the management of stable schizophrenia in the UK. METHODS: A Markov model was developed to assess the cost per quality adjusted life year (QALY) gained from 12 alternative treatment sequences each containing two atypical antipsychotics (aripiprazole (ARI), olanzapine (OLZ), quetiapine (QTP), and risperidone (RSP)), followed by clozapine. The main model parameters were populated with data from the CATIE study, which provides a direct comparison of the effectiveness of OLZ, QTP and RSP, a recent trial of ARI compared with OLZ in the long-term treatment of schizophrenia, and a recent study of diabetes incidence in atypical treated patients. Patients enter the model with stable schizophrenia. On each treatment patients may relapse, discontinue, or continue and experience adverse events (extrapyramidal symptoms, weight gain, hyperprolactinemia), or develop diabetes. Population mortality was adjusted for schizophrenia and diabetes. Utility decrements applied to stable schizophrenia, relapse, diabetes, and treatment related adverse events were taken from a direct UK utility elicitation study. Dosing for OLZ, QTP, and RSP was based on CATIE. ARI is flat priced within the ranges of 5–15 mg and 20–30 mg; we assumed a simple average of these doses. Resource use and unit costs were taken from published sources. A time horizon of 10 years was adopted. RESULTS: ARI followed by RSP produced the greatest number of QALYs, an additional 0.03 compared to RSP followed by OLZ, at an incremental cost of £222 (incremental cost per QALY: £7942). ARI followed by RSP had the greatest probability among evaluated sequences of being cost effective at a threshold of £10,000 per QALY or higher. CONCLUSION: First-line atypical treatment with aripiprazole offers a cost-effective option for patients with stable schizophrenia." @default.
• W1999808560 created "2016-06-24" @default.
• W1999808560 creator A5028081783 @default.
• W1999808560 creator A5038099139 @default.
• W1999808560 creator A5046089128 @default.
• W1999808560 creator A5066269084 @default.
• W1999808560 creator A5076957538 @default.
• W1999808560 creator A5089374907 @default.
• W1999808560 creator A5091909068 @default.
• W1999808560 date "2008-05-01" @default.
• W1999808560 modified "2023-09-26" @default.
• W1999808560 title "PMH33 COST-EFFECTIVENESS OF ARIPIPRAZOLE FOR THE MANAGEMENT OF SCHIZOPHRENIA IN THE UNITED KINGDOM" @default.
• W1999808560 doi "https://doi.org/10.1016/s1098-3015(10)70381-8" @default.
• W1999808560 hasPublicationYear "2008" @default.
• W1999808560 type Work @default.
• W1999808560 sameAs 1999808560 @default.
• W1999808560 citedByCount "1" @default.
• W1999808560 crossrefType "journal-article" @default.
• W1999808560 hasAuthorship W1999808560A5028081783 @default.
• W1999808560 hasAuthorship W1999808560A5038099139 @default.
• W1999808560 hasAuthorship W1999808560A5046089128 @default.
• W1999808560 hasAuthorship W1999808560A5066269084 @default.
• W1999808560 hasAuthorship W1999808560A5076957538 @default.
• W1999808560 hasAuthorship W1999808560A5089374907 @default.
• W1999808560 hasAuthorship W1999808560A5091909068 @default.
• W1999808560 hasBestOaLocation W19998085601 @default.
• W1999808560 hasConcept C118552586 @default.
• W1999808560 hasConcept C2776412080 @default.
• W1999808560 hasConcept C2780211496 @default.
• W1999808560 hasConcept C71924100 @default.
• W1999808560 hasConceptScore W1999808560C118552586 @default.
• W1999808560 hasConceptScore W1999808560C2776412080 @default.
• W1999808560 hasConceptScore W1999808560C2780211496 @default.
• W1999808560 hasConceptScore W1999808560C71924100 @default.
• W1999808560 hasIssue "3" @default.
• W1999808560 hasLocation W19998085601 @default.
• W1999808560 hasOpenAccess W1999808560 @default.
• W1999808560 hasPrimaryLocation W19998085601 @default.
• W1999808560 hasRelatedWork W2279161360 @default.
• W1999808560 hasRelatedWork W2351596623 @default.
• W1999808560 hasRelatedWork W2357468105 @default.
• W1999808560 hasRelatedWork W2361482857 @default.
• W1999808560 hasRelatedWork W2370041720 @default.
• W1999808560 hasRelatedWork W2385268370 @default.
• W1999808560 hasRelatedWork W2386904913 @default.
• W1999808560 hasRelatedWork W2387750902 @default.
• W1999808560 hasRelatedWork W2388570643 @default.
• W1999808560 hasRelatedWork W3031970994 @default.
• W1999808560 hasVolume "11" @default.
• W1999808560 isParatext "false" @default.
• W1999808560 isRetracted "false" @default.
• W1999808560 magId "1999808560" @default.
• W1999808560 workType "article" @default.